Dowlais Group Plc Appoints New Chief Executive to GKN Powder Metallurgy
Dowlais Group Plc, the specialist engineering firm focused on the automotive sector, has appointed Jean-Marc Durbuis as the new Chief Executive Officer of GKN Powder Metallurgy. Jean-Marc joins the company on 12 March. This appointment follows Diego Laurent’s departure from the business after 31 years of service at GKN.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312075077/en/
Jean-Marc Durbuis, Chief Executive Officer of GKN Powder Metallurgy (Photo: Business Wire)
Jean-Marc will bring extensive commercial, operational and leadership experience to GKN Powder Metallurgy as it positions itself for the transition to electric vehicles – a significant strategic opportunity for the business. Over the last 20 years, Jean-Marc has held several senior executive positions in the chemical sector, leading global teams in complex and demanding businesses. He has a proven track record across all operational functions and has been a member of several executive committees and boards.
Jean-Marc joins GKN Powder Metallurgy from Allnex, the global leading supplier of resins and additives to the coating and inks industry. He was the Executive Vice President of one of Allnex’s global divisions with revenues of over €1 billion and was a member of the Allnex Executive Committee and Board of Directors. His achievements at Allnex include delivering significant improvements in his division’s financial and operational performance, and the delivery of significant M&A projects in different geographies.
Liam Butterworth, CEO of Dowlais Group Plc, said: ‘I want to thank Diego for his 31 years at GKN. He has achieved so much during this time at both GKN Powder Metallurgy and GKN Automotive. I am particularly grateful for all he has done to maintain GKN Powder Metallurgy’s position as one of the world’s leading suppliers of powder metal materials and sintered metal components.
‘Given the critical role GKN Powder Metallurgy plays in solving complex challenges in the automotive and industrial markets, and the very exciting opportunities ahead for the business, I am delighted that Jean-Marc will join us as the new CEO. He brings a wealth of experience that will enable the Powder Metallurgy team to capture the significant opportunities before it.’
Jean-Marc said: ‘I am delighted to be joining GKN Powder Metallurgy as its new CEO. It is a world class business and will play a vital role in introducing new products to market, as we navigate the transition to EVs. I look forward to working with the team and meeting my new colleagues across the globe.’
About GKN Powder Metallurgy
GKN Powder Metallurgy solves complex challenges in automotive and industrial markets with sustainable and innovative solutions through best-in-class powder metallurgy technology. The company is a world-class provider of powder metal materials, components, applications, and electrification solutions through its three business units GKN Powders/Hoeganaes, GKN Sinter Metals and GKN Additive. GKN Powder Metallurgy is committed to sustainable goals by providing leading powder metal expertise, innovative engineering, and extensive process experience to transform ideas into production. GKN Powder Metallurgy is part of Dowlais Group plc and empowers more than 5,000 innovative thinkers in 27 locations, setting its global engineering network at the highest standard.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312075077/en/
Contact information
Press Contact for GKN Powder Metallurgy:
Christiaan Klaus
Global Strategic Marketing Manager
christiaan.klaus@gknpm.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom